(Q36763982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Amylou Dueck

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

2

Shaji Kumar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Craig Hofmeister

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jacob Laubach

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ravi Vij

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Katherine Gano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Keith Stewart

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

25 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

323-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study

24 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

Aurora kinases: new targets for cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

International uniform response criteria for multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4820359

5 September 2018

Identifiers

DOI

10.1111/BJH.13765

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26403323%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

26403323

1 reference